Designer natriuretic peptides: A vision for the future of heart failure therapeutics

Rosita Zakeri, John C Jr. Burnett

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create "designer" chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.

Original languageEnglish (US)
Pages (from-to)593-601
Number of pages9
JournalCanadian Journal of Physiology and Pharmacology
Volume89
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Natriuretic Peptides
Heart Failure
Brain Natriuretic Peptide
Therapeutics
Peptides
peptide A
Pharmacology
Kidney
Mortality

Keywords

  • CD-NP
  • Chimerics
  • CU-NP
  • Cyclic GMP
  • Heart failure
  • Natriuretic peptides

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Pharmacology

Cite this

Designer natriuretic peptides : A vision for the future of heart failure therapeutics. / Zakeri, Rosita; Burnett, John C Jr.

In: Canadian Journal of Physiology and Pharmacology, Vol. 89, No. 8, 08.2011, p. 593-601.

Research output: Contribution to journalArticle

@article{bf137d067ebd448490304b52315dc621,
title = "Designer natriuretic peptides: A vision for the future of heart failure therapeutics",
abstract = "Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create {"}designer{"} chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.",
keywords = "CD-NP, Chimerics, CU-NP, Cyclic GMP, Heart failure, Natriuretic peptides",
author = "Rosita Zakeri and Burnett, {John C Jr.}",
year = "2011",
month = "8",
doi = "10.1139/y11-048",
language = "English (US)",
volume = "89",
pages = "593--601",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "8",

}

TY - JOUR

T1 - Designer natriuretic peptides

T2 - A vision for the future of heart failure therapeutics

AU - Zakeri, Rosita

AU - Burnett, John C Jr.

PY - 2011/8

Y1 - 2011/8

N2 - Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create "designer" chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.

AB - Despite recent pharmacological advances in heart failure therapy, mortality from acute decompensated heart failure remains high. Conventional therapies are often insufficient to address the complex interplay between structural, functional, neurohumoral, and renal mechanisms involved in the heart failure syndrome. The natriuretic peptide system, however, offers a unique pleiotropic strategy which could bridge this gap in heart failure therapy. Exogenous administration of native A-type and B-type natriuretic peptides has been met with both success and limitations, and despite the limitations, remains a worthwhile endeavor. Alternatively, synthetic modification to create "designer" chimeric peptides holds the possibility to extend both the application and therapeutic benefits possible with a natriuretic peptide based approach. Herein we describe the development of natriuretic peptide based heart failure therapies, including the design, rationale, and preliminary studies of the novel chimeric peptides CD-NP and CU-NP.

KW - CD-NP

KW - Chimerics

KW - CU-NP

KW - Cyclic GMP

KW - Heart failure

KW - Natriuretic peptides

UR - http://www.scopus.com/inward/record.url?scp=79961191363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961191363&partnerID=8YFLogxK

U2 - 10.1139/y11-048

DO - 10.1139/y11-048

M3 - Article

C2 - 21815778

AN - SCOPUS:79961191363

VL - 89

SP - 593

EP - 601

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 8

ER -